MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
Key Highlights
- ➤$151.8 million acquisition of Akron Bio expands MaxCyte’s cell therapy manufacturing portfolio
- ➤Akron Bio projects 2026 revenue of approximately $28 million and EBITDA of $7-8 million
- ➤Transaction expected to nearly double MaxCyte’s revenue base and accelerate profitability
- ➤MaxCyte will pay $105.0 million cash, 20,639,733 shares, and $20.0 million deferred
- ➤New MidCap facility provides up to $75.0 million to fund operations through profitability
Expert Statements
Maher Masoud, President and Chief Executive Officer of MaxCyte
“The acquisition of Akron marks an exciting new chapter for MaxCyte”
Maher Masoud, President and Chief Executive Officer of MaxCyte
“This acquisition represents a significant step forward for us, expanding our presence across the viral and non-viral cell therapy development and manufacturing workflow, while projecting to nearly double our revenue base and accelerate our path to profitability.”
Maher Masoud, President and Chief Executive Officer of MaxCyte
“From day one, Akron provides us with an established portfolio of clinical and commercial programs supported by Akron’s DMFs and reagents.”
Maher Masoud, President and Chief Executive Officer of MaxCyte
“By bringing together two highly complementary businesses, we are diversifying our revenue base, increasing our mix of recurring revenue and expanding our exposure to the growth of commercially approved cell therapies, positioning MaxCyte for more durable near- and long-term growth.”
Maher Masoud, President and Chief Executive Officer of MaxCyte
“Like MaxCyte, Akron has become a trusted supplier to leading biopharma companies by delivering differentiated, high-quality products and best-in-class service.”
Maher Masoud, President and Chief Executive Officer of MaxCyte
“Akron is a market leader in the mission-critical consumables required for cell therapy manufacturing, including cytokines, growth factors, human plasma-derived products and media.”
Maher Masoud, President and Chief Executive Officer of MaxCyte
“We are excited to work alongside the talented Akron team as we bring together two companies to deepen customer relationships and better support cell therapy developers from development through commercialization.”
Ezequiel Zylberberg, Chief Operating Officer at Akron Bio
“We are tremendously excited by the opportunity to join these two world-class organizations, leveraging our collective experience and expertise to support our partners as they bring transformative therapies to patients around the world.”
Ezequiel Zylberberg, Chief Operating Officer at Akron Bio
“At Akron, we have always believed in earning our partners’ trust through consistent execution, uncompromising quality, and a deep commitment to the patients they serve.”
Ezequiel Zylberberg, Chief Operating Officer at Akron Bio
“As part of MaxCyte, we remain committed to delivering the quality, reliability, and innovation our partners have come to expect.”
Arcline Investment Management, Seller of Akron Bio
“Akron Bio’s success reflects the dedication of its team, and we believe MaxCyte is the best partner to drive continued growth and expand its impact on patients.”
Arcline Investment Management, Seller of Akron Bio
“Our decision to accept MaxCyte shares as part of the consideration reflects our confidence in the combined company’s long-term value and allows us to participate in its future success.”
* Akron Bio is a leading supplier of GMP-grade reagents and ancillary materials * Expands MaxCyte’s footprint across the cell therapy manufacturing workflow and establishes a combined portfolio supporting five commercially approved therapies * Akron Bio is expected to generate approximately $28 million in revenue and $7-8 million in EBITDA in 2026, with positive cash flow * MaxCyte expects the transaction to nearly double MaxCyte’s revenue base, significantly expanding commercial-stage exposure and recurring revenue, and accelerating its path to profitability
* MaxCyte secured a new credit facility with MidCap Financial of up to $75.0 million, which, together with existing cash, is expected to fund the combined company through profitability ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has entered into a definitive agreement to acquire Akron BioProducts LLC (“Akron” or “Akron Bio”) from affiliates of Arcline Investment Management (“Arcline”) for total consideration of $151.8 million. The transaction is expected to close before the end of 2026, subject to customary closing conditions.
Get started
Create a free account to read the full story.